4-HO-DPT

Klein et al. (2021) demonstrated that tryptamines with bulkier N-alkyl substituents (including N,N-dipropyl) show increased efficacy at 5-HT2B receptors. Chronic 5-HT2B agonism is the established mechanism for cardiac valvulopathy. No clinical cardiac data exists for 4-HO-DPT. Risk is theoretical and most relevant to repeated use patterns. Individuals with pre-existing cardiovascular disease face elevated baseline risk.

Lithium co-administration with serotonergic psychedelics is associated with increased seizure risk, documented in case reports involving psilocybin and LSD. The mechanism is incompletely characterized but likely involves lithium's effects on serotonin signaling combined with 5-HT2A-mediated cortical excitation. No 4-HO-DPT-specific data exists; this is a class-level contraindication recognized in standard psychedelic harm reduction guidelines.

schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, family history of psychotic spectrum disorders

5-HT2A receptor agonists can trigger acute psychotic episodes or exacerbate pre-existing psychotic conditions. This risk extends to individuals with family history of psychotic spectrum disorders. Class-level contraindication well-established across all serotonergic psychedelics; no 4-HO-DPT-specific case reports.

No reproductive safety data exists for 4-HO-DPT or any closely related 4-hydroxytryptamine analog. The effects of 5-HT2A agonism on fetal development are unexplored. This is a precautionary contraindication based on the absence of safety data rather than documented harm.

Monoamine oxidase inhibitors (MAOIs) block the primary metabolic pathway for tryptamines (MAO-A-mediated oxidative deamination). Co-administration with 4-HO-DPT would dramatically increase effective plasma levels and duration while simultaneously elevating synaptic serotonin concentrations. DPT (the parent compound) is a confirmed SERT substrate (Cozzi et al. 2009), meaning MAOI co-administration creates dual risk: blocked degradation plus transporter-mediated serotonin release. This combination is potentially fatal. Class-level contraindication — no 4-HO-DPT-specific data.

Tramadol inhibits human SERT (Baldo 2018). Combined with a serotonergic tryptamine that acts as a SERT substrate (demonstrated for DPT, Cozzi et al. 2009), this substantially increases synaptic serotonin concentrations, raising serotonin syndrome risk. Additionally, tramadol lowers seizure threshold, and DPT-class compounds show proconvulsant effects at high doses in mice (Tyagi et al. 2023). The dual serotonin toxicity plus seizure threshold reduction risk supports absolute contraindication.

fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, desvenlafaxine

SSRIs and SNRIs may attenuate psychedelic effects by altering serotonergic tone, or unpredictably modify the experience. At high doses of either agent, theoretical serotonin toxicity risk exists. The clinical significance for 4-HO-DPT specifically is unknown. Class-level contraindication.